APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Selected research

Market Analysis & Forecast

Global Duchenne Muscular Dystrophy Market Analysis and Forecast 2026-2032

21 December 2025196 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

Read the full market overview

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

This report presents an overview of global market for Duchenne Muscular Dystrophy, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Duchenne Muscular Dystrophy, also provides the sales of main regions and countries. Of the upcoming market potential for Duchenne Muscular Dystrophy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Duchenne Muscular Dystrophy sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Duchenne Muscular Dystrophy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Duchenne Muscular Dystrophy sales, projected growth trends, production technology, application and end-user industry.

Duchenne Muscular Dystrophy Segment by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy Segment by Type

Exondys 51

Emflaza

Translarna

Duchenne Muscular Dystrophy Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Duchenne Muscular Dystrophy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Exondys 51 Major Manufacturers Table 3. Emflaza Major Manufacturers Table 4. Translarna Major Manufacturers Table 5. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Manufacturers Table 7. Clinics Major Manufacturers Table 8. Home Care Major Manufacturers Table 9. Duchenne Muscular Dystrophy Industry Trends Table 10. Duchenne Muscular Dystrophy Industry Drivers Table 11. Duchenne Muscular Dystrophy Industry Opportunities and Challenges Table 12. Duchenne Muscular Dystrophy Industry Restraints Table 13. Global Duchenne Muscular Dystrophy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Duchenne Muscular Dystrophy Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Duchenne Muscular Dystrophy Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2021-2026) Table 17. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2027-2032) Table 18. Global Duchenne Muscular Dystrophy Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Doses) Table 19. Global Duchenne Muscular Dystrophy Sales by Region (2021-2026) & (K Doses) Table 20. Global Duchenne Muscular Dystrophy Sales by Region (2027-2032) & (K Doses) Table 21. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2021-2026) Table 22. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2027-2032) Table 23. Global Duchenne Muscular Dystrophy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Duchenne Muscular Dystrophy Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Duchenne Muscular Dystrophy Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers (2021-2026) Table 27. Global Duchenne Muscular Dystrophy Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 28. Global Duchenne Muscular Dystrophy Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Duchenne Muscular Dystrophy Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Duchenne Muscular Dystrophy Manufacturers, Product Type & Application Table 31. Global Duchenne Muscular Dystrophy Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Duchenne Muscular Dystrophy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Duchenne Muscular Dystrophy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2026) Table 38. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2027-2032) Table 39. Global Duchenne Muscular Dystrophy Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 40. Global Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 41. Global Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 42. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2026) Table 43. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2027-2032) Table 44. Global Duchenne Muscular Dystrophy Price by Type (2021-2026) & (USD/Dose) Table 45. Global Duchenne Muscular Dystrophy Price by Type (2027-2032) & (USD/Dose) Table 46. Global Duchenne Muscular Dystrophy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2026) Table 50. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2027-2032) Table 51. Global Duchenne Muscular Dystrophy Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 52. Global Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 53. Global Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 54. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2026) Table 55. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2027-2032) Table 56. Global Duchenne Muscular Dystrophy Price by Application (2021-2026) & (USD/Dose) Table 57. Global Duchenne Muscular Dystrophy Price by Application (2027-2032) & (USD/Dose) Table 58. Sarepta Therapeutics Company Information Table 59. Sarepta Therapeutics Business Overview Table 60. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 61. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 62. Sarepta Therapeutics Recent Development Table 63. PTC Therapeutics Company Information Table 64. PTC Therapeutics Business Overview Table 65. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 66. PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 67. PTC Therapeutics Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 71. Pfizer Duchenne Muscular Dystrophy Product Portfolio Table 72. Pfizer Recent Development Table 73. Bristol-Myers Squibb Company Information Table 74. Bristol-Myers Squibb Business Overview Table 75. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 76. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio Table 77. Bristol-Myers Squibb Recent Development Table 78. Italfarmaco Company Information Table 79. Italfarmaco Business Overview Table 80. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 81. Italfarmaco Duchenne Muscular Dystrophy Product Portfolio Table 82. Italfarmaco Recent Development Table 83. Santhera Pharmaceuticals Company Information Table 84. Santhera Pharmaceuticals Business Overview Table 85. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 86. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio Table 87. Santhera Pharmaceuticals Recent Development Table 88. North America Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (US$ Million) Table 89. North America Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (US$ Million) Table 90. North America Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 91. North America Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 92. North America Duchenne Muscular Dystrophy Sales Price by Type (2021-2026) & (USD/Dose) Table 93. North America Duchenne Muscular Dystrophy Sales Price by Type (2027-2032) & (USD/Dose) Table 94. North America Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 97. North America Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 98. North America Duchenne Muscular Dystrophy Sales Price by Application (2021-2026) & (USD/Dose) Table 99. North America Duchenne Muscular Dystrophy Sales Price by Application (2027-2032) & (USD/Dose) Table 100. North America Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 102. North America Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 103. North America Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 104. North America Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 105. North America Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 106. North America Duchenne Muscular Dystrophy Sales Price by Country (2021-2026) & (USD/Dose) Table 107. North America Duchenne Muscular Dystrophy Sales Price by Country (2027-2032) & (USD/Dose) Table 108. United States Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 109. Canada Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 110. Mexico Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 111. Europe Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 114. Europe Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 115. Europe Duchenne Muscular Dystrophy Sales Price by Type (2021-2026) & (USD/Dose) Table 116. Europe Duchenne Muscular Dystrophy Sales Price by Type (2027-2032) & (USD/Dose) Table 117. Europe Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 120. Europe Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 121. Europe Duchenne Muscular Dystrophy Sales Price by Application (2021-2026) & (USD/Dose) Table 122. Europe Duchenne Muscular Dystrophy Sales Price by Application (2027-2032) & (USD/Dose) Table 123. Europe Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. Europe Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. Europe Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 127. Europe Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 128. Europe Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 129. Europe Duchenne Muscular Dystrophy Sales Price by Country (2021-2026) & (USD/Dose) Table 130. Europe Duchenne Muscular Dystrophy Sales Price by Country (2027-2032) & (USD/Dose) Table 131. Germany Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 132. France Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 133. U.K. Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 134. Italy Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 135. Russia Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 136. Spain Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 137. Netherlands Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 138. Switzerland Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 139. Sweden Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 140. Poland Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 141. China Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (US$ Million) Table 142. China Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (US$ Million) Table 143. China Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 144. China Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 145. China Duchenne Muscular Dystrophy Sales Price by Type (2021-2026) & (USD/Dose) Table 146. China Duchenne Muscular Dystrophy Sales Price by Type (2027-2032) & (USD/Dose) Table 147. China Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (US$ Million) Table 148. China Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (US$ Million) Table 149. China Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 150. China Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 151. China Duchenne Muscular Dystrophy Sales Price by Application (2021-2026) & (USD/Dose) Table 152. China Duchenne Muscular Dystrophy Sales Price by Application (2027-2032) & (USD/Dose) Table 153. Asia Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (US$ Million) Table 154. Asia Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (US$ Million) Table 155. Asia Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 156. Asia Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 157. Asia Duchenne Muscular Dystrophy Sales Price by Type (2021-2026) & (USD/Dose) Table 158. Asia Duchenne Muscular Dystrophy Sales Price by Type (2027-2032) & (USD/Dose) Table 159. Asia Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (US$ Million) Table 160. Asia Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (US$ Million) Table 161. Asia Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 162. Asia Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 163. Asia Duchenne Muscular Dystrophy Sales Price by Application (2021-2026) & (USD/Dose) Table 164. Asia Duchenne Muscular Dystrophy Sales Price by Application (2027-2032) & (USD/Dose) Table 165. Asia Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. Asia Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 167. Asia Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 168. Asia Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 169. Asia Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 170. Asia Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 171. Asia Duchenne Muscular Dystrophy Sales Price by Country (2021-2026) & (USD/Dose) Table 172. Asia Duchenne Muscular Dystrophy Sales Price by Country (2027-2032) & (USD/Dose) Table 173. Japan Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 174. South Korea Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 175. India Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 176. Australia Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 177. Taiwan Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 178. Southeast Asia Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 179. SAMEA Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (US$ Million) Table 180. SAMEA Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (US$ Million) Table 181. SAMEA Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 182. SAMEA Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 183. SAMEA Duchenne Muscular Dystrophy Sales Price by Type (2021-2026) & (USD/Dose) Table 184. SAMEA Duchenne Muscular Dystrophy Sales Price by Type (2027-2032) & (USD/Dose) Table 185. SAMEA Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (US$ Million) Table 186. SAMEA Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (US$ Million) Table 187. SAMEA Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 188. SAMEA Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 189. SAMEA Duchenne Muscular Dystrophy Sales Price by Application (2021-2026) & (USD/Dose) Table 190. SAMEA Duchenne Muscular Dystrophy Sales Price by Application (2027-2032) & (USD/Dose) Table 191. SAMEA Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 192. SAMEA Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 193. SAMEA Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 194. SAMEA Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 195. SAMEA Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 196. SAMEA Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 197. SAMEA Duchenne Muscular Dystrophy Sales Price by Country (2021-2026) & (USD/Dose) Table 198. SAMEA Duchenne Muscular Dystrophy Sales Price by Country (2027-2032) & (USD/Dose) Table 199. Brazil Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 200. Argentina Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 201. Chile Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 202. Colombia Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 203. Peru Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 204. Saudi Arabia Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 205. Israel Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 206. UAE Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 207. Turkey Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 208. Iran Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 209. Egypt Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Table 210. Key Raw Materials Table 211. Raw Materials Key Suppliers Table 212. Duchenne Muscular Dystrophy Distributors List Table 213. Duchenne Muscular Dystrophy Customers List Table 214. Research Programs/Design for This Report Table 215. Authors List of This Report Table 216. Secondary Sources Table 217. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy Image Figure 2. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duchenne Muscular Dystrophy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Exondys 51 Image Figure 5. Emflaza Image Figure 6. Translarna Image Figure 7. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Duchenne Muscular Dystrophy Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Home Care Image Figure 12. Global Duchenne Muscular Dystrophy Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Figure 14. Global Duchenne Muscular Dystrophy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Duchenne Muscular Dystrophy Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2021-2032) Figure 17. Global Duchenne Muscular Dystrophy Sales (2021-2032) & (K Doses) Figure 18. Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 19. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Duchenne Muscular Dystrophy Sales YoY (2021-2032) & (K Doses) Figure 21. Europe Duchenne Muscular Dystrophy Sales YoY (2021-2032) & (K Doses) Figure 22. China Duchenne Muscular Dystrophy Sales YoY (2021-2032) & (K Doses) Figure 23. Asia (Excluding China) Duchenne Muscular Dystrophy Sales YoY (2021-2032) & (K Doses) Figure 24. South America, Middle East and Africa Duchenne Muscular Dystrophy Sales YoY (2021-2032) & (K Doses) Figure 25. Global Duchenne Muscular Dystrophy Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Duchenne Muscular Dystrophy Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Duchenne Muscular Dystrophy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2032) Figure 31. Global Duchenne Muscular Dystrophy Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 32. Global Duchenne Muscular Dystrophy Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2032) Figure 34. Global Duchenne Muscular Dystrophy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Duchenne Muscular Dystrophy Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2032) Figure 37. Global Duchenne Muscular Dystrophy Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 38. Global Duchenne Muscular Dystrophy Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2032) Figure 40. North America Duchenne Muscular Dystrophy Revenue Share by Type (2021-2032) Figure 41. North America Duchenne Muscular Dystrophy Sales Share by Type (2021-2032) Figure 42. North America Duchenne Muscular Dystrophy Revenue Share by Application (2021-2032) Figure 43. North America Duchenne Muscular Dystrophy Sales Share by Application (2021-2032) Figure 44. North America Duchenne Muscular Dystrophy Revenue Share by Country (2021-2032) Figure 45. North America Duchenne Muscular Dystrophy Sales Share by Country (2021-2032) Figure 46. Europe Duchenne Muscular Dystrophy Revenue Share by Type (2021-2032) Figure 47. Europe Duchenne Muscular Dystrophy Sales Share by Type (2021-2032) Figure 48. Europe Duchenne Muscular Dystrophy Revenue Share by Application (2021-2032) Figure 49. Europe Duchenne Muscular Dystrophy Sales Share by Application (2021-2032) Figure 50. Europe Duchenne Muscular Dystrophy Revenue Share by Country (2021-2032) Figure 51. Europe Duchenne Muscular Dystrophy Sales Share by Country (2021-2032) Figure 52. China Duchenne Muscular Dystrophy Revenue Share by Type (2021-2032) Figure 53. China Duchenne Muscular Dystrophy Sales Share by Type (2021-2032) Figure 54. China Duchenne Muscular Dystrophy Revenue Share by Application (2021-2032) Figure 55. China Duchenne Muscular Dystrophy Sales Share by Application (2021-2032) Figure 56. Asia Duchenne Muscular Dystrophy Revenue Share by Type (2021-2032) Figure 57. Asia Duchenne Muscular Dystrophy Sales Share by Type (2021-2032) Figure 58. Asia Duchenne Muscular Dystrophy Revenue Share by Application (2021-2032) Figure 59. Asia Duchenne Muscular Dystrophy Sales Share by Application (2021-2032) Figure 60. Asia Duchenne Muscular Dystrophy Revenue Share by Country (2021-2032) Figure 61. Asia Duchenne Muscular Dystrophy Sales Share by Country (2021-2032) Figure 62. SAMEA Duchenne Muscular Dystrophy Revenue Share by Type (2021-2032) Figure 63. SAMEA Duchenne Muscular Dystrophy Sales Share by Type (2021-2032) Figure 64. SAMEA Duchenne Muscular Dystrophy Revenue Share by Application (2021-2032) Figure 65. SAMEA Duchenne Muscular Dystrophy Sales Share by Application (2021-2032) Figure 66. SAMEA Duchenne Muscular Dystrophy Revenue Share by Country (2021-2032) Figure 67. SAMEA Duchenne Muscular Dystrophy Sales Share by Country (2021-2032) Figure 68. Duchenne Muscular Dystrophy Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Duchenne Muscular Dystrophy Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys 51
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Duchenne Muscular Dystrophy Market by Type
  3. 1.2.1 Global Duchenne Muscular Dystrophy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Exondys 51
  5. 1.2.3 Emflaza
  6. 1.2.4 Translarna
  7. 1.3 Duchenne Muscular Dystrophy Market by Application
  8. 1.3.1 Global Duchenne Muscular Dystrophy Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Home Care
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Duchenne Muscular Dystrophy Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Duchenne Muscular Dystrophy Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Duchenne Muscular Dystrophy Revenue by Region
  3. 3.2.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Duchenne Muscular Dystrophy Revenue by Region (2021-2026)
  5. 3.2.3 Global Duchenne Muscular Dystrophy Revenue by Region (2027-2032)
  6. 3.2.4 Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Duchenne Muscular Dystrophy Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Duchenne Muscular Dystrophy Sales by Region
  9. 3.4.1 Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Duchenne Muscular Dystrophy Sales by Region (2021-2026)
  11. 3.4.3 Global Duchenne Muscular Dystrophy Sales by Region (2027-2032)
  12. 3.4.4 Global Duchenne Muscular Dystrophy Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturers
  2. 4.1.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Duchenne Muscular Dystrophy Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Duchenne Muscular Dystrophy Sales by Manufacturers
  6. 4.2.1 Global Duchenne Muscular Dystrophy Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Duchenne Muscular Dystrophy Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Duchenne Muscular Dystrophy Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Duchenne Muscular Dystrophy Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Duchenne Muscular Dystrophy Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Duchenne Muscular Dystrophy Manufacturers, Product Type & Application
  13. 4.7 Global Duchenne Muscular Dystrophy Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Duchenne Muscular Dystrophy Market CR5 and HHI
  16. 4.8.2 2025 Duchenne Muscular Dystrophy Tier 1, Tier 2, and Tier 3
5 Duchenne Muscular Dystrophy Market by Type
  1. 5.1 Global Duchenne Muscular Dystrophy Revenue by Type
  2. 5.1.1 Global Duchenne Muscular Dystrophy Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Duchenne Muscular Dystrophy Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Duchenne Muscular Dystrophy Sales by Type
  6. 5.2.1 Global Duchenne Muscular Dystrophy Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Duchenne Muscular Dystrophy Sales by Type (2021-2032) & (K Doses)
  8. 5.2.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2032)
  9. 5.3 Global Duchenne Muscular Dystrophy Price by Type
6 Duchenne Muscular Dystrophy Market by Application
  1. 6.1 Global Duchenne Muscular Dystrophy Revenue by Application
  2. 6.1.1 Global Duchenne Muscular Dystrophy Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Duchenne Muscular Dystrophy Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Duchenne Muscular Dystrophy Sales by Application
  6. 6.2.1 Global Duchenne Muscular Dystrophy Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Duchenne Muscular Dystrophy Sales by Application (2021-2032) & (K Doses)
  8. 6.2.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2032)
  9. 6.3 Global Duchenne Muscular Dystrophy Price by Application
7 Company Profiles
  1. 7.1 Sarepta Therapeutics
  2. 7.1.1 Sarepta Therapeutics Company Information
  3. 7.1.2 Sarepta Therapeutics Business Overview
  4. 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  6. 7.1.5 Sarepta Therapeutics Recent Developments
  7. 7.2 PTC Therapeutics
  8. 7.2.1 PTC Therapeutics Company Information
  9. 7.2.2 PTC Therapeutics Business Overview
  10. 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  12. 7.2.5 PTC Therapeutics Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Italfarmaco
  26. 7.5.1 Italfarmaco Company Information
  27. 7.5.2 Italfarmaco Business Overview
  28. 7.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
  30. 7.5.5 Italfarmaco Recent Developments
  31. 7.6 Santhera Pharmaceuticals
  32. 7.6.1 Santhera Pharmaceuticals Company Information
  33. 7.6.2 Santhera Pharmaceuticals Business Overview
  34. 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
  36. 7.6.5 Santhera Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Duchenne Muscular Dystrophy Market Size by Type
  2. 8.1.1 North America Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
  3. 8.1.2 North America Duchenne Muscular Dystrophy Sales by Type (2021-2032)
  4. 8.1.3 North America Duchenne Muscular Dystrophy Price by Type (2021-2032)
  5. 8.2 North America Duchenne Muscular Dystrophy Market Size by Application
  6. 8.2.1 North America Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
  7. 8.2.2 North America Duchenne Muscular Dystrophy Sales by Application (2021-2032)
  8. 8.2.3 North America Duchenne Muscular Dystrophy Price by Application (2021-2032)
  9. 8.3 North America Duchenne Muscular Dystrophy Market Size by Country
  10. 8.3.1 North America Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Duchenne Muscular Dystrophy Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Duchenne Muscular Dystrophy Market Size by Type
  2. 9.1.1 Europe Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
  3. 9.1.2 Europe Duchenne Muscular Dystrophy Sales by Type (2021-2032)
  4. 9.1.3 Europe Duchenne Muscular Dystrophy Price by Type (2021-2032)
  5. 9.2 Europe Duchenne Muscular Dystrophy Market Size by Application
  6. 9.2.1 Europe Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
  7. 9.2.2 Europe Duchenne Muscular Dystrophy Sales by Application (2021-2032)
  8. 9.2.3 Europe Duchenne Muscular Dystrophy Price by Application (2021-2032)
  9. 9.3 Europe Duchenne Muscular Dystrophy Market Size by Country
  10. 9.3.1 Europe Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Duchenne Muscular Dystrophy Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Duchenne Muscular Dystrophy Market Size by Type
  2. 10.1.1 China Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
  3. 10.1.2 China Duchenne Muscular Dystrophy Sales by Type (2021-2032)
  4. 10.1.3 China Duchenne Muscular Dystrophy Price by Type (2021-2032)
  5. 10.2 China Duchenne Muscular Dystrophy Market Size by Application
  6. 10.2.1 China Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
  7. 10.2.2 China Duchenne Muscular Dystrophy Sales by Application (2021-2032)
  8. 10.2.3 China Duchenne Muscular Dystrophy Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Duchenne Muscular Dystrophy Market Size by Type
  2. 11.1.1 Asia Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
  3. 11.1.2 Asia Duchenne Muscular Dystrophy Sales by Type (2021-2032)
  4. 11.1.3 Asia Duchenne Muscular Dystrophy Price by Type (2021-2032)
  5. 11.2 Asia Duchenne Muscular Dystrophy Market Size by Application
  6. 11.2.1 Asia Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
  7. 11.2.2 Asia Duchenne Muscular Dystrophy Sales by Application (2021-2032)
  8. 11.2.3 Asia Duchenne Muscular Dystrophy Price by Application (2021-2032)
  9. 11.3 Asia Duchenne Muscular Dystrophy Market Size by Country
  10. 11.3.1 Asia Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Duchenne Muscular Dystrophy Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Duchenne Muscular Dystrophy Market Size by Type
  2. 12.1.1 SAMEA Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Duchenne Muscular Dystrophy Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Duchenne Muscular Dystrophy Price by Type (2021-2032)
  5. 12.2 SAMEA Duchenne Muscular Dystrophy Market Size by Application
  6. 12.2.1 SAMEA Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Duchenne Muscular Dystrophy Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Duchenne Muscular Dystrophy Price by Application (2021-2032)
  9. 12.3 SAMEA Duchenne Muscular Dystrophy Market Size by Country
  10. 12.3.1 SAMEA Duchenne Muscular Dystrophy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Duchenne Muscular Dystrophy Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Duchenne Muscular Dystrophy Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Duchenne Muscular Dystrophy Value Chain Analysis
  2. 13.1.1 Duchenne Muscular Dystrophy Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Duchenne Muscular Dystrophy Production Mode & Process
  6. 13.2 Duchenne Muscular Dystrophy Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Duchenne Muscular Dystrophy Distributors
  9. 13.2.3 Duchenne Muscular Dystrophy Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst